RU2015114990A - Способы, композиции и приборы для облегчения регенерации - Google Patents

Способы, композиции и приборы для облегчения регенерации Download PDF

Info

Publication number
RU2015114990A
RU2015114990A RU2015114990/10A RU2015114990A RU2015114990A RU 2015114990 A RU2015114990 A RU 2015114990A RU 2015114990/10 A RU2015114990/10 A RU 2015114990/10A RU 2015114990 A RU2015114990 A RU 2015114990A RU 2015114990 A RU2015114990 A RU 2015114990A
Authority
RU
Russia
Prior art keywords
antibody
conjugated
toxin
humanized
cell
Prior art date
Application number
RU2015114990/10A
Other languages
English (en)
Other versions
RU2640249C2 (ru
Inventor
Льюис С. ГРУБЕР
Original Assignee
Сива Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сива Корпорейшн filed Critical Сива Корпорейшн
Publication of RU2015114990A publication Critical patent/RU2015114990A/ru
Application granted granted Critical
Publication of RU2640249C2 publication Critical patent/RU2640249C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin
    • A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N7/02—Localised ultrasound hyperthermia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Electromagnetism (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)

Abstract

1. Гуманизированное антитело, которое связывается с конечным продуктом гликирования клетки.2. Гуманизированное антитело по п. 1, где антитело является моноклональным антителом.3. Гуманизированное антитело по п. 1, где антитело конъюгировано с токсином.4. Гуманизированное антитело по п. 2, где антитело конъюгировано с токсином.5. Применение антитела, которое связывается с конечным продуктом гликирования клетки, для промотирования регенерации ткани или органа у пациента путем уничтожения частично функциональных или не функциональных клеток, которые содержат указанный конечный продукт гликирования клетки.6. Применение по п. 5, где антитело является гуманизированным.7. Применение по п. 5, где антитело является моноклональным антителом.8. Применение по п. 5, где антитело конъюгировано с токсином.9. Применение по п. 6, где антитело является моноклональным антителом.10. Применение по п. 6, где антитело конъюгировано с токсином.11. Применение по п. 7, где антитело конъюгировано с токсином.12. Применение по п. 9, где антитело конъюгировано стоксином.13. Применение композиции для промотирования регенеративных процессов или для преодоления эффектов старения, где композиция селективно уничтожает стареющие клетки, при этом композиция содержит антитела, которые связываются с конечным продуктом гликирования клетки.14. Применение по п. 13, где антитело является гуманизированным.15. Применение по п. 13, где антитело является моноклональным антителом.16. Применение по п. 13, где антитело конъюгировано с токсином.17. Применение по п. 14, где антитело является моноклональным антителом.18. Применение по п. 14, где антитело конъюгировано с токсином.19. Приме�

Claims (20)

1. Гуманизированное антитело, которое связывается с конечным продуктом гликирования клетки.
2. Гуманизированное антитело по п. 1, где антитело является моноклональным антителом.
3. Гуманизированное антитело по п. 1, где антитело конъюгировано с токсином.
4. Гуманизированное антитело по п. 2, где антитело конъюгировано с токсином.
5. Применение антитела, которое связывается с конечным продуктом гликирования клетки, для промотирования регенерации ткани или органа у пациента путем уничтожения частично функциональных или не функциональных клеток, которые содержат указанный конечный продукт гликирования клетки.
6. Применение по п. 5, где антитело является гуманизированным.
7. Применение по п. 5, где антитело является моноклональным антителом.
8. Применение по п. 5, где антитело конъюгировано с токсином.
9. Применение по п. 6, где антитело является моноклональным антителом.
10. Применение по п. 6, где антитело конъюгировано с токсином.
11. Применение по п. 7, где антитело конъюгировано с токсином.
12. Применение по п. 9, где антитело конъюгировано с
токсином.
13. Применение композиции для промотирования регенеративных процессов или для преодоления эффектов старения, где композиция селективно уничтожает стареющие клетки, при этом композиция содержит антитела, которые связываются с конечным продуктом гликирования клетки.
14. Применение по п. 13, где антитело является гуманизированным.
15. Применение по п. 13, где антитело является моноклональным антителом.
16. Применение по п. 13, где антитело конъюгировано с токсином.
17. Применение по п. 14, где антитело является моноклональным антителом.
18. Применение по п. 14, где антитело конъюгировано с токсином.
19. Применение по п. 15, где антитело конъюгировано с токсином.
20. Применение по п. 17, где антитело конъюгировано с токсином.
RU2015114990A 2008-05-23 2009-05-22 Способы, композиции и приборы для облегчения регенерации RU2640249C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5584608P 2008-05-23 2008-05-23
US61/055,846 2008-05-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2010152693/10A Division RU2553225C2 (ru) 2008-05-23 2009-05-22 Способ облегчения регенерации

Publications (2)

Publication Number Publication Date
RU2015114990A true RU2015114990A (ru) 2015-11-27
RU2640249C2 RU2640249C2 (ru) 2017-12-27

Family

ID=41340916

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010152693/10A RU2553225C2 (ru) 2008-05-23 2009-05-22 Способ облегчения регенерации
RU2015114990A RU2640249C2 (ru) 2008-05-23 2009-05-22 Способы, композиции и приборы для облегчения регенерации

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2010152693/10A RU2553225C2 (ru) 2008-05-23 2009-05-22 Способ облегчения регенерации

Country Status (18)

Country Link
US (4) US20110105961A1 (ru)
EP (3) EP2294178B1 (ru)
JP (6) JP2011521009A (ru)
KR (4) KR20120127543A (ru)
CN (2) CN102037119B (ru)
AU (1) AU2009248945B2 (ru)
BR (1) BRPI0913047A2 (ru)
CA (1) CA2724886C (ru)
DK (1) DK2789684T3 (ru)
ES (2) ES2499395T3 (ru)
HU (1) HUE031902T2 (ru)
IL (3) IL209513A (ru)
MX (2) MX2010012473A (ru)
PL (1) PL2789684T3 (ru)
PT (1) PT2789684T (ru)
RU (2) RU2553225C2 (ru)
WO (1) WO2009143411A2 (ru)
ZA (1) ZA201008209B (ru)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10226531B2 (en) 2010-09-27 2019-03-12 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US10960234B2 (en) 2010-11-22 2021-03-30 Siwa Corporation Selective removal of cells having accumulated agents
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102037119B (zh) 2008-05-23 2015-06-24 Siwa有限公司 促进再生的方法、组合物及设备
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
CA2859385A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
BR112015024605A2 (pt) 2013-03-24 2017-07-18 Oisin Biotechnologies sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
BR112018007422A2 (pt) 2015-10-13 2018-10-30 Siwa Corp anticorpos anti-age e métodos de uso dos mesmos
IL283726B2 (en) 2016-02-19 2025-05-01 Siwa Corp A preparation containing an antibody to advanced glycation end products (AGE) for use in the treatment of breast cancer
EP3443007A1 (en) * 2016-04-15 2019-02-20 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
WO2018129563A1 (en) 2017-01-09 2018-07-12 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
EP3619540A1 (en) 2017-05-04 2020-03-11 Siwa Corporation Diagnostic advanced glycation end-product antibodies
WO2019204666A1 (en) 2018-04-18 2019-10-24 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
EP3826670A1 (en) 2018-07-23 2021-06-02 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
WO2020041625A1 (en) * 2018-08-23 2020-02-27 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
KR20210101481A (ko) * 2020-02-10 2021-08-19 한국과학기술연구원 초음파 출력부를 포함하는 노화세포 제거 장치
US20230181730A1 (en) 2020-05-01 2023-06-15 Siwa Corporation Methods of treating infections
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
KR102650316B1 (ko) * 2021-06-18 2024-03-25 재단법인대구경북과학기술원 초음파 자극이 가능한 자성 패치 및 그 제작 방법
CA3229602A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
WO2024102157A1 (en) 2022-11-09 2024-05-16 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
DE102025104920B3 (de) 2025-02-11 2026-03-05 Thyssenkrupp Steel Europe Ag Verfahren zum Herstellen einer Dressierwalze, Dressierwalze sowie Verfahren zum Dressieren eines schmelztauchbeschichteten Stahlbands
DE102025104918B3 (de) 2025-02-11 2026-03-05 Thyssenkrupp Steel Europe Ag Verfahren zum Herstellen einer Dressierwalze, Dressierwalze sowie Verfahren zum Dressieren eines schmelztauchbeschichteten Stahlbands

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US5811075A (en) 1984-03-19 1998-09-22 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US4900747A (en) * 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
JP2644767B2 (ja) * 1986-09-12 1997-08-25 ザ ロックフェラー ユニバーシティ 後生的なグリコシル化最終産物を除去する為の方法及び薬剤
US4917951A (en) * 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4965288A (en) * 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IN172208B (ru) * 1990-04-02 1993-05-01 Sint Sa
US20080063603A1 (en) * 1990-04-02 2008-03-13 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20040208826A1 (en) * 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
ATE144124T1 (de) * 1991-12-20 1996-11-15 Technomed Medical Systems Schallwellen aussendende,thermische effekte und kavitationseffekte erzeugende vorrichtung fur die ultraschalltherapie
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5620479A (en) * 1992-11-13 1997-04-15 The Regents Of The University Of California Method and apparatus for thermal therapy of tumors
US5518720A (en) * 1992-12-30 1996-05-21 Exocell, Inc. Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US6387373B1 (en) * 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
EP0753071A1 (en) * 1993-04-28 1997-01-15 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
AU693992B2 (en) * 1994-12-30 1998-07-09 Alteon Inc. Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
US5744318A (en) * 1994-12-30 1998-04-28 Alteon Inc. Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
AU6907496A (en) 1995-08-25 1997-03-19 Case Western Reserve University Process for detecting pentosidine and for assessing the biological age of a biological sample
JP3579549B2 (ja) 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5664570A (en) 1996-02-20 1997-09-09 Svc Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5984882A (en) * 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6245318B1 (en) * 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
WO1999007893A1 (en) 1997-08-08 1999-02-18 University Of Washington ISOLATION OF A NOVEL SENESCENCE-FACTOR GENE, p23
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6896659B2 (en) * 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
JP4016304B2 (ja) 1998-02-26 2007-12-05 日本油脂株式会社 モノクローナル抗体、ハイブリッド細胞、およびモノクローナル抗体の製造方法
WO1999064463A1 (en) * 1998-06-09 1999-12-16 Alteon Inc. Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6309355B1 (en) * 1998-12-22 2001-10-30 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
PT1159003E (pt) 1999-03-02 2011-02-22 Centocor Inc Anti-tnf alfa na terapêutica da asma resistente a esteróides
US6067859A (en) 1999-03-04 2000-05-30 The Board Of Regents, The University Of Texas System Optical stretcher
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
JP2003507013A (ja) * 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
EP1219639A4 (en) 1999-09-08 2009-03-25 Toray Industries CIPO - Patent
US6853864B2 (en) 2000-02-02 2005-02-08 Catholic University Of America, The Use of electromagnetic fields in cancer and other therapies
WO2001089584A2 (en) * 2000-05-23 2001-11-29 Amersham Health As Contrast agents
NO312338B1 (no) * 2000-08-25 2002-04-29 Gunnar Myhr Anordning for selektiv celle- eller virusödeleggelse hos en levende organisme
CN2445326Y (zh) * 2000-10-09 2001-08-29 刘永详 测定被糖化蛋白的免疫分析装置
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7481781B2 (en) * 2000-11-17 2009-01-27 Gendel Limited Ultrasound therapy
US6821274B2 (en) * 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
US7347855B2 (en) 2001-10-29 2008-03-25 Ultrashape Ltd. Non-invasive ultrasonic body contouring
WO2002054018A2 (en) 2001-01-03 2002-07-11 Ultrashape Inc. Non-invasive ultrasonic body contouring
DE60202008T2 (de) * 2001-03-22 2005-12-01 Roche Diagnostics Gmbh Verfahren zum Auffinden von Reagenzien und Festphasenkomponenten in spezifischen Bindungsassays, frei von fortgeschrittenen Glykosylierungsendprodukten
JPWO2003008446A1 (ja) 2001-07-19 2004-11-11 三菱ウェルファーマ株式会社 後期糖化産物受容体のシグナル伝達に関連するポリペプチド
JP4012722B2 (ja) 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1542997B1 (en) * 2002-07-24 2012-02-29 Dermira (Canada), Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
MXPA05001758A (es) 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2004079368A2 (en) * 2003-03-08 2004-09-16 Auvation Ltd Markers for colorectal cancer
US20060122543A1 (en) * 2003-07-31 2006-06-08 Woodwelding Ag Method for promoting tissue regeneration on wound surfaces as device and treatment instrument or implant for carrying out method
US7358226B2 (en) * 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules
EP1715897B2 (en) * 2004-01-20 2013-10-30 Sunnybrook and Women's College Health Sciences Centre High frequency ultrasound imaging using contrast agents
EP1753861A4 (en) * 2004-02-17 2010-03-10 Dynamis Therapeutics Inc FRUCTOSAMINE-3-KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
ES2473587T3 (es) 2004-08-03 2014-07-07 Transtech Pharma, Inc. Proteínas de fusión de RAGE y métodos de uso
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1866663A1 (en) * 2005-03-03 2007-12-19 Bracco Research S.A. Medical imaging system based on a targeted contrast agent
JP2006249015A (ja) * 2005-03-11 2006-09-21 Mochida Pharmaceut Co Ltd 細胞老化抑制剤
WO2006109599A1 (ja) 2005-04-05 2006-10-19 Jms Co., Ltd. 3,4-DGEに由来するAGEsに特異的に反応する抗体
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
WO2007027584A2 (en) * 2005-08-30 2007-03-08 University Of Virginia Patent Foundation Deposit contrast agents and related methods thereof
US20070065415A1 (en) * 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
US20070083120A1 (en) * 2005-09-22 2007-04-12 Cain Charles A Pulsed cavitational ultrasound therapy
US20070078290A1 (en) * 2005-09-30 2007-04-05 Esenaliev Rinat O Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues
US7766833B2 (en) * 2005-11-23 2010-08-03 General Electric Company Ablation array having independently activated ablation elements
JP4779115B2 (ja) 2005-12-16 2011-09-28 国立大学法人東北大学 早期肺癌の術後予後検査方法
EP1988918A4 (en) * 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
WO2008154638A2 (en) 2007-06-12 2008-12-18 Board Of Regents, The University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)
US8398977B2 (en) 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
JP2007277263A (ja) 2007-07-13 2007-10-25 Transgenic Inc カルボキシメチル化タンパク質に対する抗体
US20120156134A1 (en) * 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
US7751057B2 (en) * 2008-01-18 2010-07-06 The Board Of Trustees Of The University Of Illinois Magnetomotive optical coherence tomography
DE102008009461A1 (de) 2008-02-15 2009-08-20 Beiersdorf Ag Verfahren zur Reduzierung der Zeichen der Hautalterung
CN102089430B (zh) 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
CN102037119B (zh) 2008-05-23 2015-06-24 Siwa有限公司 促进再生的方法、组合物及设备
JP5229473B2 (ja) * 2008-06-04 2013-07-03 財団法人ヒューマンサイエンス振興財団 超音波医療装置
US20110319499A1 (en) 2008-06-30 2011-12-29 The Johns Hopkins University Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
WO2010095461A1 (ja) 2009-02-20 2010-08-26 国立大学法人東京大学 新規モノクローナル抗体、並びにその使用
WO2011035104A1 (en) * 2009-09-17 2011-03-24 Sanuwave, Inc. Methods and devices for cleaning and sterilization with shock waves
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
EP2493486A1 (en) 2009-10-30 2012-09-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
WO2011101039A1 (en) 2010-02-22 2011-08-25 Universite Pierre Et Marie Curie (Paris 6) Apparatus for the treatment of brain affections and method implementing thereof
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
WO2012047629A2 (en) 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012135616A1 (en) 2011-03-31 2012-10-04 Siwa Corporation Vaccination against advanced glycation end-products
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
US20130012816A1 (en) 2011-07-10 2013-01-10 Guided Therapy Systems, Llc Methods and systems for controlling acoustic energy deposition into a medium
US8954155B2 (en) 2011-09-19 2015-02-10 Biotalk Technologies Inc Apparatus and method for rejuvenating skin
JP2014534169A (ja) 2011-09-23 2014-12-18 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓエピトープ結合部位を形成するペプチドまたはペプチドの配置
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
CN105017420B (zh) 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
US20130288980A1 (en) 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent and cancer cells for selective killing by interference with foxo4
US10379026B2 (en) 2012-08-29 2019-08-13 Inguran, Llc Cell processing using magnetic particles
KR101520336B1 (ko) 2012-11-30 2015-05-14 전남대학교산학협력단 패혈증 비브리오균의 편모 구성성분인 플라젤린과 병원체의 항원 단백을 융합시킨 재조합 단백을 포함하는 노화 예방, 개선 또는 치료용 조성물
EP2742935A1 (en) 2012-12-14 2014-06-18 Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH SERF2 for the treatment of atrophy and for increasing cell growth
EP2964668B1 (en) 2013-03-06 2019-11-27 Protalix Ltd. Tnf alpha inhibitor polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US20140257262A1 (en) 2013-03-11 2014-09-11 Alexandre Carpentier Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
AU2015206515B2 (en) 2014-01-15 2019-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cartilage targeting agents and their use
US10099027B2 (en) 2014-01-24 2018-10-16 Cole Research & Design Oral suction device
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
DE102014107077B3 (de) 2014-05-20 2015-08-13 Ecs Engineered Control Systems Ag Schaltvorrichtung
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US20170240632A1 (en) 2014-10-16 2017-08-24 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
BR112018007422A2 (pt) 2015-10-13 2018-10-30 Siwa Corp anticorpos anti-age e métodos de uso dos mesmos
KR102503910B1 (ko) 2015-11-09 2023-02-27 삼성전자주식회사 기립 보조 방법 및 장치
IL283726B2 (en) 2016-02-19 2025-05-01 Siwa Corp A preparation containing an antibody to advanced glycation end products (AGE) for use in the treatment of breast cancer
US10981021B2 (en) 2016-03-11 2021-04-20 Carthera Method for transiently disrupting a region of the blood-brain barrier of a human
EP3443007A1 (en) 2016-04-15 2019-02-20 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10858449B1 (en) * 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
BR112019021471A2 (pt) 2017-04-13 2020-05-12 Siwa Corporation Anticorpo monoclonal humanizado de produto final da glicação avançada
EP3619540A1 (en) 2017-05-04 2020-03-11 Siwa Corporation Diagnostic advanced glycation end-product antibodies
EP3826670A1 (en) 2018-07-23 2021-06-02 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
KR20210045435A (ko) 2018-08-14 2021-04-26 이멜 바이오테라퓨틱스, 인코포레이티드. 미토콘드리아 질환 또는 장애 및 헤테로플라스미를 치료하기 위한 방법 및 조성물
WO2020041625A1 (en) 2018-08-23 2020-02-27 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
US20230181730A1 (en) 2020-05-01 2023-06-15 Siwa Corporation Methods of treating infections
WO2021247397A2 (en) 2020-06-04 2021-12-09 Siwa Corporation Methods and compositions for enhancing the immune system

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226531B2 (en) 2010-09-27 2019-03-12 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US10960234B2 (en) 2010-11-22 2021-03-30 Siwa Corporation Selective removal of cells having accumulated agents
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US11873345B2 (en) 2014-12-18 2024-01-16 Siwa Corporation Product and method for treating sarcopenia
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Also Published As

Publication number Publication date
IL209513A0 (en) 2011-01-31
EP2294178B1 (en) 2014-07-16
US20120183534A1 (en) 2012-07-19
US9161810B2 (en) 2015-10-20
KR20120127543A (ko) 2012-11-21
KR20110000585A (ko) 2011-01-03
EP2789684B1 (en) 2016-12-21
JP2011521009A (ja) 2011-07-21
HK1150628A1 (en) 2012-01-06
ES2499395T3 (es) 2014-09-29
IL240242A0 (en) 2015-09-24
KR20150041158A (ko) 2015-04-15
HK1200485A1 (en) 2015-08-07
JP2022089873A (ja) 2022-06-16
AU2009248945A1 (en) 2009-11-26
PT2789684T (pt) 2017-02-14
MX342994B (es) 2016-10-21
JP2017125073A (ja) 2017-07-20
JP6637465B2 (ja) 2020-01-29
HUE031902T2 (en) 2017-08-28
WO2009143411A2 (en) 2009-11-26
RU2010152693A (ru) 2012-06-27
JP2020050666A (ja) 2020-04-02
EP2294178A4 (en) 2011-12-07
CA2724886C (en) 2017-11-14
IL209513A (en) 2015-08-31
JP2016152815A (ja) 2016-08-25
BRPI0913047A2 (pt) 2013-03-05
JP6359051B2 (ja) 2018-07-18
JP2015131846A (ja) 2015-07-23
CA2724886A1 (en) 2009-11-26
US20180111982A2 (en) 2018-04-26
CN102037119B (zh) 2015-06-24
RU2640249C2 (ru) 2017-12-27
US20160152697A1 (en) 2016-06-02
CN104987416A (zh) 2015-10-21
MX2010012473A (es) 2011-02-23
IL248652A0 (en) 2016-12-29
KR101592156B1 (ko) 2016-02-04
CN102037119A (zh) 2011-04-27
WO2009143411A3 (en) 2010-01-14
US20110105961A1 (en) 2011-05-05
EP2789684A1 (en) 2014-10-15
US20180044411A1 (en) 2018-02-15
AU2009248945B2 (en) 2014-02-13
KR101537460B1 (ko) 2015-07-16
DK2789684T3 (en) 2017-02-20
EP3170888A1 (en) 2017-05-24
RU2553225C2 (ru) 2015-06-10
ES2616728T3 (es) 2017-06-14
PL2789684T3 (pl) 2017-06-30
ZA201008209B (en) 2012-04-25
US11261241B2 (en) 2022-03-01
KR20130132658A (ko) 2013-12-04
EP2294178A2 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
BR112014027659A2 (pt) anticorpos específicos para cll-1
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
CR11783A (es) Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno
EP2860192A3 (en) Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
MX2022012083A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
EA200800812A1 (ru) Композиции антитела против cd3
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
UA103499C2 (ru) Антитело против интерлейкина-17 (ил-17) человека и его применение
UY31710A (es) Anticuerpos monoclonales y su método de obtención
EA200870265A1 (ru) Функционально активные антитела
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
UA109633C2 (uk) Антитіло людини проти тканинного фактора
PE20091261A1 (es) Anticuerpos anti-hepcidina
UA98332C2 (ru) Гуманизированное антитело к cd44, которое опосредует цитотоксичность в отношении раковых клеток
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
AR069980A1 (es) Inmunoconjugados dirigidos contra cd 138 y sus usos
RU2014149553A (ru) Биспецифические анти-vegf/анти-ang-2 антитела
MX358705B (es) Agentes de union de esclerostina.
EA201400579A1 (ru) Антитела к il-36r
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
EA201070687A1 (ru) Способ ингибирования лейкозных стволовых клеток
AR079944A1 (es) Anticuerpo neutralizante de la actividad de un anticoagulante
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы